International, Multi-Center, Open-label, Treatment Extension Study of Iniparib as Monotherapy or in Combination Chemotherapeutic Regimens in Cancer Patients Who Have Derived Clinical Benefit From Iniparib Following Completion of a Phase 1, 2 or 3 Parental Study
Phase of Trial: Phase III
Latest Information Update: 03 Apr 2017
At a glance
- Drugs Iniparib (Primary) ; Carboplatin; Doxorubicin liposomal; Gemcitabine; Irinotecan; Paclitaxel; Topotecan
- Indications Cancer
- Focus Adverse reactions
- Sponsors Sanofi
- 03 Oct 2016 Status changed from active, no longer recruiting to completed.
- 21 Jun 2016 Planned End Date changed from 1 Jun 2016 to 1 Sep 2016.
- 21 Jun 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Sep 2016.